MARKETS / NASDAQ / CDNA
NASDAQ · SERVICES-MEDICAL LABORATORIES · LARGE CAP

Caredx, Inc. CDNA

14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$379.8M
▲ 13.8% vs FY2024
EPS · FY25
$-0.40
Dividend / sh · FY25
Payout · FY25
ROE · FY25
-6.3%
Net margin · FY25
-5.6%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 379.8M
Revenue, FY2025 · full 14-year series below
Revenue Net income
0.10.20.30.40.4-0.0201220152018202120242025
0.10.20.30.40.4-0.02016201920222025

The company lost 6 cents on every revenue dollar this year.

Per share
USD -0.40
Diluted EPS, FY2025
EPS
0.40.81.2-0.40201220152018202120242025
0.40.81.2-0.402016201920222025

The company pays no cash dividend.

Profitability
-6.3%
Return on equity, FY2025
ROE
5101520-6.3%201220152018202120242025
5101520-6.3%2016201920222025
Operating margin-8.1%
Net margin-5.6%
Return on assets-4.7%

Each USD of equity lost 6 cents this year.

Returned to shareholders
USD 82.0M
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacksUSD 82.0M
Share of profit-384.2%
Consecutive raises

USD 82.0M in buybacks went back to shareholders in a year without profit.

Growth
+14.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.7%
+14.6%
+29.7%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.05B
Shares outstanding, FY2025
0.000.05201220152018202120242025
0.020.052016201920222025
Change, 5 years+3.0%
Change, 10 years

The share count grew 3% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 413.2M
total assets, end of FY2025
Total assetsUSD 413.2M
EquityUSD 303.1M
CashUSD 65.4M
Current ratio2.86×

Equity funds 73% of total assets.

History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
0.4
0.3
0.3
0.3
0.3
0.2
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
0.0
−0.2
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
EBITDA $B
−0.0
0.1
−0.2
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
Net income $B
−0.0
0.1
−0.2
−0.1
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
0.0
−0.0
−0.0
EPS, diluted $
−0.40
0.93
−3.54
−1.44
−0.59
−0.40
−0.52
−1.31
−2.38
−2.39
−1.16
0.10
−3.50
−5.01
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−6.3
16.4
−55.0
−17.1
−8.2
−9.9
−22.5
−104.1
−831.1
−161.2
−38.7
·
·
·
Shares out B
0.05
0.05
0.05
0.05
0.05
0.05
0.04
0.04
0.03
0.02
0.01
0.01
0.00
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed